News | April 28, 2026
AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care
The approval was driven by data from the Phase III TULIP-SC trial
The approval was driven by data from the Phase III TULIP-SC trial
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Subscribe To Our Newsletter & Stay Updated
